Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19816 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Dimitrios Rigopoulos und 20 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Dermatology-Venereology, University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Quality of Life. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: LEO Pharma.
Abstract (Originalsprache)
Background
Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real‐life data remain scarce. BrIDGE was an observational, prospective, single‐cohort, multicentre study that recruited patients with moderate‐to severe plaque psoriasis in Greece.
Objectives
The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short‐term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12–16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.
Methods
Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, ‘worst case’ and ‘best case’ scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables.
Results
Based on the ‘as observed data’, 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12–16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12–16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%.
Conclusions
Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate‐to‐severe psoriasis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1st Department of Dermatology-Venereology, University of Athens, Athens, Greece.
- Dermatological Department, Tzaneio General Hospital, Piraeus, Greece.
- Department of Dermatology, Athens Naval Hospital, Athens, Greece.
- 2nd Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Private Physician, Athens, Greece.
- Department of Dermatology, Medical School, General University Hospital, University of Patras, Patras, Greece.
ORCID-Profile: Dimitrios Rigopoulos, Eleftheria Tampouratzi, Zoe Apalla, Florentina Delli, Elisavet Lazaridou, Evangelia Papadavid, Elena Sotiriou, Dimitrios Ioannides
Förderung
- LEO Pharma
Zitieren
APA
Rigopoulos, D., Tampouratzi, E., Angelakopoulos, C., Apalla, Z., Barkis, I., Georgiou, S., Delli, F., Drosos, A., Zafiriou, E., Katsantonis, J., Lazaridou, E., Panagakis, P., Papadavid, E., Papakonstantis, M., Roussaki-Schulze, A. V., Sotiriou, E., Anastasiadis, G., Chasapi, V., Sfaelos, K., …, & BrIDGE Study Group (2024). Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19816
Vancouver
Rigopoulos D, Tampouratzi E, Angelakopoulos C, Apalla Z, Barkis I, Georgiou S, et al. Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study). Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19816
BibTeX
@article{Rigopoulos2024,
author = {Rigopoulos, Dimitrios and Tampouratzi, Eleftheria and Angelakopoulos, Charalampos and Apalla, Zoe and Barkis, Ioannis and Georgiou, Sophia and Delli, Florentina and Drosos, Alexandros and Zafiriou, Efterpi and Katsantonis, John and Lazaridou, Elisavet and Panagakis, Pantelis and Papadavid, Evangelia and Papakonstantis, Markos and Roussaki-Schulze, Angeliki-Viktoria and Sotiriou, Elena and Anastasiadis, Georgios and Chasapi, Vasiliki and Sfaelos, Konstantinos and Ioannides, Dimitrios and BrIDGE Study Group, BrIDGE Study Group},
title = {Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19816}
}
EUVIMED